The question of whether Rubius Therapeutics Inc. would disclose data with its cellular therapy, RTX-240, ahead of the American Association for Cancer Research (AACR) meeting next month was answered in a market-satisfying way as the Cambridge, Mass.-based firm rolled out positive findings from the ongoing phase I/II experiment. Read More
Elevatebio LLC, a provider of infrastructure, expertise and investment for a growing roster of cell and gene therapy companies, has raised $525 million in series C financing to advance its work. Matrix Capital Management led the round, joined by new investors Softbank Vision Fund 2 and Fidelity Management and Research Co. Existing investors also joined in. Read More
Intec Pharma Ltd. is merging with privately held Decoy Biosystems Inc. and the combined company will continue advancing Decoy’s immunotherapy technology for treating a variety of tumors and chronic viral infections. Read More
After working 24/7 to develop a COVID-19 vaccine in a historic timeframe and scale up manufacturing at an unprecedented rate, some vaccine manufacturers are now facing what appears to be a concerted Russian misinformation campaign akin to those used in the last two U.S. presidential campaigns, as well as in Great Britain and possibly in France. Read More
A large-scale metabolomics study of blood samples from 11,000 people has identified common biological links among a number of chronic non-communicable diseases, opening up the possibility of countering multiple diseases simultaneously. Read More
While World Trade Organization members continue to debate a proposal to waive intellectual property rights for COVID-19 vaccines and therapies, Biolyse Pharma Corp. is threatening to apply for a compulsory license of Johnson & Johnson’s one-dose vaccine through the Canadian Access to Medicines Regime. Read More
The latest global regulatory news, changes and updates affecting biopharma, including: FDA launches EUA safety dashboard; Fed Circuit claims mandamus jurisdiction in IPR institution; Comment period reopened on Orange Book patents. Read More
New hires and promotions in the biopharma industry, including: Alx, Ardelyx, Aulos, Eledon, IGM, Minovia, Modus, Panbela, Reneo, Silverback, Xbrane. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Bioxcel, Calliditas, Histogen, Melinta, Oryzon, Pharmaessentia, Tetra. Read More
